EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of PDS Biotechnology.

    Client Virtual Booth

    PDS BIOTECHNOLOGY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    PDS Biotechnology
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    The Ruth Group 757 Third Avenue New York NY 10017
    Telephone
    Telephone
    (646) 536 7000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pdsbiotech.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PDS Biotech: Data Update from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

    Details:

    Versamune, is a novel investigational HPV-targeted immunotherapy, which is currently being investigated in combination with pembrolizumab for head and neck cancer.


    Lead Product(s): PDS0101,Pembrolizumab

    Therapeutic Area: Oncology Product Name: Versamune-HPV

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 12, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-positive Head and Neck Cancer

    Details:

    PDS0101, is a novel investigational HPV-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers, it is being investigated with pembrolizumab for head and neck cancer.


    Lead Product(s): PDS0101,Pembrolizumab

    Therapeutic Area: Oncology Product Name: Versamune-HPV

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 09, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive C...

    Details:

    PDS0101, PDS Biotech’s lead candidate, is a Versamune® based investigational immunotherapy designed to stimulate a potent targeted T cell attack against HPV16-positive cancers.


    Lead Product(s): PDS0101,M7824,NHS-IL12

    Therapeutic Area: Oncology Product Name: PDS0101

    Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 09, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined wi...

    Details:

    PDS0301 is a novel investigational tumor-targeting antibody drug conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency and longevity of T cells and natural killer (NK) cells in the tumor microenvironment.


    Lead Product(s): PDS0301,Docetaxel

    Therapeutic Area: Oncology Product Name: PDS0301

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 11, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in ...

    Details:

    PDS0101, PDS Biotech’s lead candidate, is a novel investigational human papillomavirus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers.


    Lead Product(s): PDS0101,Pembrolizumab

    Therapeutic Area: Oncology Product Name: PDS0101

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 03, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

    Details:

    PDS0202 combines PDS Biotech’s Infectimune® novel investigational immune activating platform with proprietary Computationally Optimized Broadly Reactive Antigens (COBRA) influenza antigens.


    Lead Product(s): PDS0202

    Therapeutic Area: Infections and Infectious Diseases Product Name: PDS0202

    Highest Development Status: PreclinicalProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 20, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

    Details:

    PDS0101 is a novel investigational human papillomavirus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and neck cancer.


    Lead Product(s): PDS0101,Pembrolizumab

    Therapeutic Area: Oncology Product Name: PDS0101

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 14, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck C...

    Details:

    PDS0101 is a novel investigational human papillomavirus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers.


    Lead Product(s): PDS0101,Pembrolizumab

    Therapeutic Area: Oncology Product Name: PDS0101

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 14, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and N...

    Details:

    PDS0101 is a novel investigational human papillomavirus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers.


    Lead Product(s): PDS0101,Pembrolizumab

    Therapeutic Area: Oncology Product Name: PDS0101

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Merck & Co

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor

    Details:

    PDS0101 is a novel investigational human papilloma virus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers.


    Lead Product(s): PDS0101,PDS0301,Undisclosed

    Therapeutic Area: Oncology Product Name: PDS0101

    Highest Development Status: IND EnablingProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    aspen-api-m-2024-08-19

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search